Special Drug Use Surveillance of Irribow in Female Patients

Astellas

Status: Completed

Conditions: Diarrhea-predominant Irritable Bowel Syndrome

Treatments: Drug: Ramosetron

Study type: Observational

Funder types: Industry

Identifiers

NCT02612649

IB0002

Details and patient eligibility

About

The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.

Enrollment: 793 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female patients with diarrhea-predominant irritable bowel syndrome

Exclusion criteria

Trial design

793 participants in 1 patient group

Ramosetron group

Description:

Female patients with diarrhea-predominant irritable bowel syndrome

Treatment:

Drug: Ramosetron